NantHealth Acquires OpenNMS, the World’s Largest Open Source Network Management Application Platform
July 27 2020 - 8:00AM
Business Wire
NantHealth, Inc. (NASDAQ: NH), a next-generation,
evidence-based, personalized healthcare company, today announced
the acquisition of The OpenNMS Group, Inc. (www.opennms.com), the
world’s premier open-source network management company, which will
operate as a subsidiary of NantHealth. The transaction closed on
July 22, 2020.
“OpenNMS has set the standard for open-source network monitoring
since 2000 with its enterprise-grade network management platform,”
said Ron Louks, Chief Operating Officer, NantHealth. “We are
thrilled to have them join the NantHealth family.
“This acquisition not only expands and diversifies NantHealth’s
software portfolio and service offerings, but it expands our
company-wide capabilities in cloud, SaaS and AI technologies.
OpenNMS, we believe, will provide our customers with a new world
class set of services to maintain reliable network connections for
critical data flows that enable patient data collaboration and
decision making at the point of care.”
Based in Morrisville, NC, OpenNMS provides a highly reliable,
scalable and comprehensive fault, performance and traffic
monitoring solution that easily integrates with business
applications and workflows to monitor and visualize everything in a
network. The OpenNMS platform monitors some of the largest networks
in existence, covering the healthcare, technology, finance,
government, education, retail and industrial sectors, many with
tens of thousands of networked devices. OpenNMS customers include
three of the top 5 companies on the Fortune 100, as well as
multiple large and multi-state health providers and one of the
largest electronic medical record providers in the United
States.
“I’m delighted for our organization to join the talented team of
software and artificial intelligence engineers at NantHealth, which
will enable OpenNMS to accelerate our adoption of machine learning
and data science technologies,” said David Hustace, CEO of OpenNMS.
“This transaction strengthens our internal capabilities as we move
to offer SaaS-based solutions to our customers across all
industries, while also expanding our penetration in the healthcare
industry.”
The OpenNMS platform provides key insights and analytics
regarding network performance and availability needed for
organizations to maintain uptime across multiple environments,
geographies and devices. Platform features include:
- Event Management. OpenNMS can serve as the central
repository and correlation system for system logs and notifications
from all devices on a network.
- Fault Management. OpenNMS actively monitors latency and
tests the availability of all devices on a network using over 30
different protocols as synthetic transactions, which are further
analyzed by unique machine and deep learning technologies imbedded
in its Architecture for Learning Enabled Correlation (ALEC).
- Performance Measurement. OpenNMS can collect and receive
streams of telemetry (time-series) data from devices on a network
via multiple protocols: HTTP, SNMP, JMX, WMI/ws-man, gRPC, gpb over
UDP. This data can be stored, graphed and measured for thresholds
and streamed to Kafka for integration with other enterprise
systems.
- Traffic Management. OpenNMS provides a highly scalable
solution for actively monitoring and correlating network flows in
conjunction with its fault and performance data.
OpenNMS is continuing to expand its best-in-industry reliability
and scalability through creation of cloud solutions and services,
implementation of hardware appliances for expansion of edge
monitoring, continued investment in its AI/ML enabled ALEC
solution, and addition of advanced route monitoring solutions
driving more data for ALEC.
About NantHealth
NantHealth, a member of the NantWorks ecosystem of companies,
provides leading solutions across the continuum of care for
physicians, payers, patients and biopharmaceutical organizations.
NantHealth enables the use of cutting-edge data and technology
toward the goals of empowering clinical decision support and
improving patient outcomes. NantHealth’s comprehensive product
portfolio combines the latest technology in payer/provider
platforms that exchange information in near-real time (NaviNet and
Eviti), and molecular profiling services that combine comprehensive
DNA & RNA tumor-normal profiling with pharmacogenomics analysis
(GPS Cancer®). For more information, please visit
www.nanthealth.com or follow us on Twitter, Facebook and
LinkedIn.
Forward-Looking Statements
This news release contains certain statements of a
forward-looking nature relating to future events or future business
performance. Forward-looking statements can be identified by the
words “expects,” “anticipates,” “believes,” “intends,” “estimates,”
“plans,” “will,” “outlook” and similar expressions. Forward-looking
statements are based on management’s current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. Risks and uncertainties include, but are not limited to: our
ability to successfully integrate a complex learning system to
address a wide range of healthcare issues; our ability to
successfully amass the requisite data to achieve maximum network
effects; appropriately allocating financial and human resources
across a broad array of product and service offerings; raising
additional capital as necessary to fund our operations; achieving
significant commercial market acceptance for our sequencing and
molecular analysis solutions; establish relationships with, key
thought leaders or payers’ key decision makers in order to
establish GPS Cancer as a standard of care for patients with
cancer; our ability to grow the market for our Systems
Infrastructure, and applications; successfully enhancing our
Systems Infrastructure and applications to achieve market
acceptance and keep pace with technological developments; customer
concentration; competition; security breaches; bandwidth
limitations; our ability to continue our relationship with
NantOmics; our ability to obtain regulatory approvals; dependence
upon senior management; the need to comply with and meet applicable
laws and regulations; unexpected adverse events; clinical adoption
and market acceptance of GPS Cancer; and anticipated cost savings.
We undertake no obligation to update any forward-looking statement
in light of new information or future events, except as otherwise
required by law. Forward-looking statements involve inherent risks
and uncertainties, most of which are difficult to predict and are
generally beyond our control. Actual results or outcomes may differ
materially from those implied by the forward-looking statements as
a result of the impact of a number of factors, many of which are
discussed in more detail in our reports filed with the Securities
and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200727005225/en/
NANT Jen Hodson Jen@nant.com 562-397-3639
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Mar 2024 to Apr 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Apr 2023 to Apr 2024